Related Experiment Videos
Ten-year heart transplantation experience at the MARITIME HEART CENTER: does volume affect results?
J F Légaré1, H Haddad, S Haddad
1Dalhousie University, Halifax, Canada. jflegare@hotmail.com
Insights
This study shows excellent survival rates for heart transplantation at a Canadian center, comparable to international standards. Key factors like HLA-DR matching and donor BMI may improve outcomes.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Small-volume heart transplant centers face unique challenges.
- Evaluating outcomes is crucial for quality improvement.
Purpose of the Study:
- To assess the outcomes of primary heart transplantation at a Canadian center.
- To identify factors influencing patient survival post-transplant.
Main Methods:
- A retrospective analysis of 94 primary heart transplants performed between 1988 and 1998.
- Kaplan-Meier survival analysis was employed for outcome assessment.
Main Results:
- One-year survival was 85.9%, and five-year survival was 75.3%.
- Trends suggested improved survival with HLA-DR matching, favorable BMI ratio, shorter ischemic times, and male donors.
- No significant impact on survival was observed for donor/recipient age, recipient sex, or pre-existing conditions like hypertension.
Conclusions:
- The center achieved excellent one- and five-year survival rates post-heart transplantation.
- These results are comparable to those reported by the International Society for Heart and Lung Transplantation.
Objective:
To evaluate the experience of a small volume Canadian heart transplantation centre.
Design:
Ninety-four consecutive primary heart transplants were performed from 1988 to 1998 at the Maritime Heart Center, Halifax, Nova Scotia, with 100% follow-up. Kaplan-Meier survival analysis was used.
Results:
The mean recipient age was 48.5+/-12.3 years and donor age 33+/-13.2 years. Eighty per cent of recipients were men. The prevalence of elevated pulmonary vascular resistance (4 or more Wood units) was 20.2%. Etiology of heart failure was ischemic cardiomyopathy (50%), dilated cardiomyopathy (40.9%) and congenital heart disease (9.1%). Survival was 85.9% at one year (n=71), 75.3% at five years (n=33) and 60.5% at eight years (n=8). There was a trend toward survival benefit with human leukocyte antigen (HLA) -DR matching, body mass index ratio of donor to recipient greater than 0.8, ischemic time less than 90 mins and male donors. There was no effect on survival with donor or recipient age, recipient sex, diabetes, hypertension, hypercholesterolemia, elevated pulmonary vascular resistance and HLA-A/B mismatch.
Conclusions:
Excellent survival at one and five years following heart transplantation is reported that compares favourably with results published by the International Society for Heart and Lung Transplantation.